{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T19:49:47Z","timestamp":1775936987701,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97920-5","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:28:26Z","timestamp":1744604906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of 18F-FDG and 68Ga-DOTA-IBA in detecting bone metastases: a lesion-basis study"],"prefix":"10.1038","volume":"15","author":[{"given":"Linwei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengsai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"8 Suppl","key":"97920_CR1","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman, R. E. Skeletal complications of malignancy. Cancer 80 (8 Suppl), 1588\u20131594 (1997).","journal-title":"Cancer"},{"issue":"12","key":"97920_CR2","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/jbmr.3618","volume":"33","author":"J Fornetti","year":"2018","unstructured":"Fornetti, J., Welm, A. L. & Stewart, S. A. Understanding the bone in cancer metastasis. J. Bone Min. Res. 33 (12), 2099\u20132113 (2018).","journal-title":"J. Bone Min. Res."},{"issue":"2","key":"97920_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/pcan.2011.7","volume":"14","author":"N Sathiakumar","year":"2011","unstructured":"Sathiakumar, N. et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: A population-based analysis of US medicare beneficiaries, 1999\u20132006. Prostate Cancer Prostatic Dis. 14 (2), 177\u2013183 (2011).","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"11","key":"97920_CR4","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00259-005-1842-8","volume":"32","author":"T Nakai","year":"2005","unstructured":"Nakai, T. et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in participants with breast cancer. Eur. J. Nucl. Med. Mol. Imaging. 32 (11), 1253\u20131258 (2005).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"97920_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00003495-199957010-00011","volume":"57","author":"M Dooley","year":"1999","unstructured":"Dooley, M. & Balfour, J. A. Ibandronate. Drugs 57 (1), 101\u2013110. (1999).","journal-title":"Drugs"},{"key":"97920_CR6","doi-asserted-by":"publisher","first-page":"1027792","DOI":"10.3389\/fonc.2022.1027792","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA. Front. Oncol. 12, 1027792 (2022).","journal-title":"Front. Oncol."},{"issue":"6","key":"97920_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/RLU.0000000000004634","volume":"48","author":"L Qiu","year":"2023","unstructured":"Qiu, L. et al. Safety and efficacy of 68 Ga- or 177 Lu-Labeled DOTA-IBA as a novel theranostic radiopharmaceutical for bone metastases: A phase 0\/I study. Clin. Nucl. Med. 48 (6), 489\u2013496 (2023).","journal-title":"Clin. Nucl. Med."},{"issue":"10","key":"97920_CR8","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/RLU.0000000000004757","volume":"48","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. Biodistribution and internal dosimetry of 68 Ga-DOTA-IBA PET imaging for participants with bone metastases. Clin. Nucl. Med. 48 (10), 847\u2013852 (2023).","journal-title":"Clin. Nucl. Med."},{"issue":"12","key":"97920_CR9","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.2967\/jnumed.118.211102","volume":"59","author":"LM Peterson","year":"2018","unstructured":"Peterson, L. M. et al. Prospective study of serial 18F-FDG PET and 18F-Fluoride PET to predict time to Skeletal-Related events, time to progression, and survival in patients with bone-dominant metastatic breast cancer. J. Nucl. Med. 59 (12), 1823\u20131830 (2018).","journal-title":"J. Nucl. Med."},{"issue":"1","key":"97920_CR10","doi-asserted-by":"publisher","first-page":"29501","DOI":"10.1038\/s41598-024-81350-w","volume":"14","author":"X Mu","year":"2024","unstructured":"Mu, X. et al. 18F-NaF uptake in skull-base bone as a predictor of treatment response in advanced nasopharyngeal carcinoma. Sci. Rep. 14 (1), 29501 (2024).","journal-title":"Sci. Rep."},{"issue":"4","key":"97920_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00259-018-4223-9","volume":"46","author":"GK Azad","year":"2019","unstructured":"Azad, G. K. et al. Prediction of therapy response in bone-predominant metastatic breast cancer: Comparison of [18F] Fluorodeoxyglucose and [18F]-fluoride PET\/CT with whole-body MRI with diffusion-weighted imaging. Eur. J. Nucl. Med. Mol. Imaging. 46 (4), 821\u2013830 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"97920_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11307-017-1132-4","volume":"20","author":"A Letellier","year":"2018","unstructured":"Letellier, A. et al. Uptake of Radium-223 dichloride and early [18F]NaF PET response are driven by baseline [18F]NaF parameters: A pilot study in castration-resistant prostate cancer patients. Mol. Imaging Biol. 20 (3), 482\u2013491 (2018).","journal-title":"Mol. Imaging Biol."},{"issue":"1091","key":"97920_CR13","doi-asserted-by":"publisher","first-page":"20170948","DOI":"10.1259\/bjr.20170948","volume":"91","author":"H Jadvar","year":"2018","unstructured":"Jadvar, H. & Colletti, P. M. 18F-NaF\/223RaCl2 theranostics in metastatic prostate cancer: Treatment response assessment and prediction of outcome. Br. J. Radiol. 91 (1091), 20170948 (2018).","journal-title":"Br. J. Radiol."},{"key":"97920_CR14","doi-asserted-by":"publisher","first-page":"1364311","DOI":"10.3389\/fonc.2024.1364311","volume":"14","author":"J Deng","year":"2024","unstructured":"Deng, J., Yang, J., Wang, Y., Liu, G. & Chen, Y. Comparison of the relative diagnostic performance of 68Ga-DOTA-IBA and 18F-NaF for the detection of bone metastasis. Front. Oncol. 14, 1364311 (2024).","journal-title":"Front. Oncol."},{"key":"97920_CR15","doi-asserted-by":"publisher","first-page":"1428498","DOI":"10.3389\/fonc.2024.1428498","volume":"14","author":"F Xiang","year":"2024","unstructured":"Xiang, F. et al. Prospective comparison of 68Ga-DOTA-ibandronate and bone scans for detecting bone metastases in breast cancer. Front. Oncol. 14, 1428498 (2024).","journal-title":"Front. Oncol."},{"key":"97920_CR16","doi-asserted-by":"publisher","first-page":"737827","DOI":"10.3389\/fonc.2021.737827","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu, J. et al. Comparison of the relative diagnostic performance of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET\/CT for the detection of bone metastasis in patients with different cancers. Front. Oncol. 11, 737827 (2021).","journal-title":"Front. Oncol."},{"issue":"8","key":"97920_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s12149-024-01935-3","volume":"38","author":"H Arak","year":"2024","unstructured":"Arak, H., Elboga, U., Cayirli, Y. B. & Aytekin, A. Prognostic significance of 68 Ga-FAPI PET\/CT in patients with bone metastases in various cancers. Ann. Nucl. Med. 38 (8), 630\u2013638 (2024).","journal-title":"Ann. Nucl. Med."},{"key":"97920_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-024-01714-0","author":"X Tian","year":"2024","unstructured":"Tian, X. et al. Evaluating the diagnostic value of 18F-FAPI-04 PET\/CT in various malignant tumors: A head-to-head comparison with 18F-FDG PET\/CT. Jpn J. Radiol. https:\/\/doi.org\/10.1007\/s11604-024-01714-0(2024).","journal-title":"Jpn J. Radiol."},{"issue":"4","key":"97920_CR19","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.3390\/ijms24043863","volume":"24","author":"MMA Sidrak","year":"2023","unstructured":"Sidrak, M. M. A. et al. Fibroblast activation protein inhibitor (FAPI)-based theranostics-where we are at and where we are heading: A systematic review. Int. J. Mol. Sci. 24 (4), 3863 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"97920_CR20","doi-asserted-by":"publisher","first-page":"111302","DOI":"10.1016\/j.ejrad.2024.111302","volume":"171","author":"G Wu","year":"2024","unstructured":"Wu, G. et al. Head-to-head comparison of [68Ga]Ga-FAPI PET and [18F]FDG PET in the detection of bone and lymph node metastasis in various cancers: A systematic review and meta-analysis. Eur. J. Radiol. 171, 111302 (2024).","journal-title":"Eur. J. Radiol."},{"issue":"2","key":"97920_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00259-021-05472-3","volume":"49","author":"C Qin","year":"2022","unstructured":"Qin, C. et al. Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: Metastases and beyond. Eur. J. Nucl. Med. Mol. Imaging. 49 (2), 709\u2013720 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"97920_CR22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s00259-018-3936-0","volume":"45","author":"C Sachpekidis","year":"2018","unstructured":"Sachpekidis, C. et al. 68Ga-PSMA PET\/CT in the evaluation of bone metastases in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 45 (6), 904\u2013912 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"97920_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jmir.2023.04.005","volume":"54","author":"H Daniels","year":"2023","unstructured":"Daniels, H., Gilbert, R. & Bonin, L. The diagnostic accuracy of 68Ga-PSMA PET\/CT versus 99mTc-MDP bone scintigraphy for identifying bone metastases in persons with prostate cancer: A systematic review. J. Med. Imaging Radiat. Sci. 54 (3), 545\u2013555 (2023).","journal-title":"J. Med. Imaging Radiat. Sci."},{"issue":"4","key":"97920_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/01.RLU.0000057556.54046.7A","volume":"28","author":"Y Nakamoto","year":"2003","unstructured":"Nakamoto, Y., Osman, M. & Wahl, R. L. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin. Nucl. Med. 28 (4), 302\u2013307 (2003).","journal-title":"Clin. Nucl. Med."},{"issue":"1","key":"97920_CR25","first-page":"62","volume":"60","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues, M. et al. Diagnostic performance of [18F] FDG PET-CT compared to bone scintigraphy for the detection of bone metastases in lung cancer patients. Q. J. Nucl. Med. Mol. Imaging. 60 (1), 62\u201368 (2016).","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"97920_CR26","doi-asserted-by":"publisher","first-page":"8271313","DOI":"10.1155\/2018\/8271313","volume":"2018","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Comparison of 18F-NaF PET\/CT and 18F-FDG PET\/CT for detection of Skull-Base invasion and osseous metastases in nasopharyngeal carcinoma. Contrast Media Mol. Imaging. 2018, 8271313 (2018).","journal-title":"Contrast Media Mol. Imaging"},{"issue":"5","key":"97920_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clon.2010.10.002","volume":"23","author":"T Liu","year":"2011","unstructured":"Liu, T. et al. Fluorine-18 Deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: Which one is the best?--a meta-analysis. Clin. Oncol. (R Coll. Radiol). 23 (5), 350\u2013358 (2011).","journal-title":"Clin. Oncol. (R Coll. Radiol)"},{"issue":"5","key":"97920_CR28","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.ejrad.2011.01.126","volume":"81","author":"X Qu","year":"2012","unstructured":"Qu, X., Huang, X., Yan, W., Wu, L. & Dai, K. A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur. J. Radiol. 81 (5), 1007\u20131015 (2012).","journal-title":"Eur. J. Radiol."},{"issue":"2","key":"97920_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.suronc.2013.01.002","volume":"22","author":"J Rong","year":"2013","unstructured":"Rong, J. et al. Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg. Oncol. 22 (2), 86\u201391 (2013).","journal-title":"Surg. Oncol."},{"issue":"6C","key":"97920_CR30","first-page":"4439","volume":"25","author":"H Kato","year":"2005","unstructured":"Kato, H. et al. Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas. Anticancer Res. 25 (6\u00a0C), 4439\u20134444 (2005).","journal-title":"Anticancer Res."},{"issue":"3","key":"97920_CR31","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1148\/radiology.199.3.8638000","volume":"199","author":"PD Shreve","year":"1996","unstructured":"Shreve, P. D., Grossman, H. B., Gross, M. D. & Wahl, R. L. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199 (3), 751\u2013756 (1996).","journal-title":"Radiology"},{"issue":"5","key":"97920_CR32","first-page":"242","volume":"15","author":"AK Pietrzak","year":"2018","unstructured":"Pietrzak, A. K., Czepczynski, R., Wierzchoslawska, E. & Cholewinski, W. Detection of the prostate Cancer bone metastases: Is it feasible to compare 18F-fluorocholine PET\/CT, 18F-fluorodeoxyglucose PET\/CT and 99mTc-methyl diphosphonate bone scintigraphy?? Urol. J. 15 (5), 242\u2013247 (2018).","journal-title":"Urol. J."},{"issue":"6","key":"97920_CR33","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/0969-8051(96)00044-3","volume":"23","author":"SDJ Yeh","year":"1996","unstructured":"Yeh, S. D. J. et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl. Med. Biol. 23 (6), 693\u2013697 (1996).","journal-title":"Nucl. Med. Biol."},{"issue":"10","key":"97920_CR34","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1200\/JCO.1998.16.10.3375","volume":"16","author":"GJ Cook","year":"1998","unstructured":"Cook, G. J., Houston, S., Rubens, R., Maisey, M. N. & Fogelman, I. Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J. Clin. Oncol. 16 (10), 3375\u20133379 (1998).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"97920_CR35","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00259-005-1842-8","volume":"32","author":"T Nakai","year":"2005","unstructured":"Nakai, T. et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur. J. Nucl. Med. Mol. Imaging. 32 (11), 1253\u20131258 (2005).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"97920_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ejrad.2009.01.036","volume":"74","author":"N Liu","year":"2010","unstructured":"Liu, N. et al. Bone metastasis in patients with non-small cell lung cancer: The diagnostic role of F-18 FDG PET\/CT. Eur. J. Radiol. 74, 231 (2010).","journal-title":"Eur. J. Radiol"},{"issue":"2","key":"97920_CR37","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1148\/radiol.2372031994","volume":"237","author":"Y Nakamoto","year":"2005","unstructured":"Nakamoto, Y., Cohade, C., Tatsumi, M., Hammoud, D. & Wahl, R. L. CT appearance of bone metastases detected with FDG PET as part of the same PET\/CT examination. Radiology 237 (2), 627\u2013634 (2005).","journal-title":"Radiology"},{"issue":"6","key":"97920_CR38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/MNM.0b013e328338e909","volume":"31","author":"T \u00d6z\u00fclker","year":"2010","unstructured":"\u00d6z\u00fclker, T., K\u00fc\u00e7\u00fck\u00f6z Uzun, A., \u00d6z\u00fclker, F. & \u00d6zpa\u00e7ac, T. Comparison of 18F-FDG-PET\/CT with 99mTc-MDP bone scintigraphy for the detection of bone metastases in cancer patients. Nucl. Med. Commun. 31 (6), 597\u2013603 (2010).","journal-title":"Nucl. Med. Commun."},{"issue":"2","key":"97920_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1022627421000","volume":"20","author":"MP Roudier","year":"2003","unstructured":"Roudier, M. P. et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results. Clin. Exp. Metastasis. 20 (2), 171\u2013180 (2003).","journal-title":"Clin. Exp. Metastasis"},{"issue":"7","key":"97920_CR40","first-page":"1039","volume":"34","author":"M Pecherstorfer","year":"1993","unstructured":"Pecherstorfer, M. et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J. Nucl. Med. 34 (7), 1039\u20131044 (1993).","journal-title":"J. Nucl. Med."},{"issue":"1","key":"97920_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3816\/CBC.2010.n.004","volume":"10","author":"PG Morris","year":"2010","unstructured":"Morris, P. G. et al. Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results. Clin. Breast. Cancer. 10 (1), 33\u201339 (2010).","journal-title":"Clin. Breast. Cancer."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97920-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97920-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97920-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:28:27Z","timestamp":1744604907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97920-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97920"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97920-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the ethics committee of the affiliated hospital of southwest medical university and registered on Clinical Trial Registry (Clinical ethics registration number: ChiCTR2200064487). All procedures performed in studies in involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all subjects and\/or their legal guardian(s).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"12766"}}